American Journal of Kidney Diseases
Volume 52, Issue 6 , Pages 1039-1041 , December 2008

Erythropoietin-Stimulating Agents: Ongoing Concerns With Safety

  • Mark Crowther, MD, MSc, FRCPC

      Affiliations

    • Corresponding Author InformationAddress correspondence to Mark Crowther, MD, MSc, FRCPC, Room L208, St Joseph's Hospital, 50 Charlton Ave, East Hamilton, Ontario, Canada L0R 1T0
    • ,
  • Ghazala Radwi, MD

References 

  1. Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol. 2008;141:287–297
  2. Locatelli F, Pozzoni P, Vecchio LD. Recombinant human epoetin beta in the treatment of renal anemia. Ther Clin Risk Manag. 2007;3:433–439
  3. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2006;3:CD003407
  4. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914–924
  5. Agency for Healthcare Research and Quality. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=4&DocID=35Accessed July 26, 2008
  6. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  7. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  8. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357:965–976
  9. US Food and Drug Administration. FDA issues complete response letters ordering safety labeling changes under FDAAA for Aranesp, Epogen, and Procrit. http://www.fda.gov/cder/drug/infopage/RHE/default.htmAccessed October 15, 2008
  10. US Food and Drug Administration. Aranesp package insert. http://www.fda.gov/cder/drug/infopage/RHE/aranesp/packageinsert.pdfAccessed October 17, 2008
  11. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008;111:25–41

PII: S0272-6386(08)01476-5

doi: 10.1053/j.ajkd.2008.10.006

American Journal of Kidney Diseases
Volume 52, Issue 6 , Pages 1039-1041 , December 2008

Article Tools